Researchers at Hadhramout University in Mukalla, Yemen, conducted a retrospective cross-sectional study of 106 patients admitted to the COVID-19 isolation centers at Ibn-Sina Hospital between 1 December 2021 and 30 October 2022. The cohort comprised 63 men and 43 women with a mean age of 58.3 years, and all participants had presented with clinical suspicion of COVID-19 and undergone SARS-CoV-2 RT-PCR testing on nasal or oropharyngeal swabs. Of these, 58 patients, or 54.72 percent, tested positive and were classified as confirmed cases, while 48 patients, or 45.28 percent, tested negative and were classified as suspected cases. To guard against false negatives, patients with initial negative results were retested within 48 to 72 hours, a precaution the authors argue strengthens the reliability of the negative classification.

The study, published in Acta Biochimica Polonica, was designed to compare a panel of routine hematological and biochemical parameters between the two groups. The investigators extracted demographic, clinical, hematological, and biochemical data from electronic medical records and analyzed complete blood counts alongside random blood glucose, alanine transaminase, aspartate transaminase, lactate dehydrogenase, gamma-glutamyl transferase, C-reactive protein, and ferritin. Patients with known liver disease, renal disease, hematological disorders, autoimmune diseases, or malignancies were excluded, since any of these conditions could independently distort the laboratory picture and confound the comparison.

The hematological findings were striking. Compared with the RT-PCR-negative group, patients with confirmed COVID-19 had significantly higher hemoglobin, hematocrit, red blood cell counts, and white blood cell counts. Their neutrophil counts were markedly elevated, while lymphocyte and eosinophil counts were significantly reduced. This pattern, combining neutrophilia with lymphopenia and eosinopenia, mirrors what has been described repeatedly in confirmed COVID-19 cases worldwide and is thought to reflect the systemic inflammatory response triggered by SARS-CoV-2. Lymphopenia in particular has emerged as one of the most consistent hematological signatures of the disease, and reduced eosinophil levels have been linked to inflammatory activity and delayed recovery in prior reports.

Not every measured parameter moved in the same direction. Mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet counts, monocyte counts, and basophil counts showed no statistically significant differences between the two groups. This selectivity is itself informative, suggesting that the laboratory changes associated with confirmed infection are not a nonspecific derangement of the blood but a characteristic pattern concentrated in the white cell differential and in the oxygen-carrying components. The authors note that hemoglobin and hematocrit were higher in the confirmed group, consistent with some previous studies, although other investigations have reported declining hemoglobin with increasing disease severity, a discrepancy the researchers attribute to differences in disease stage, patient characteristics, and underlying comorbidities.

The biochemical results were equally revealing. Serum levels of lactate dehydrogenase, gamma-glutamyl transferase, C-reactive protein, and ferritin were all significantly higher in the RT-PCR-positive group, with P values below 0.001 for each comparison. Random blood glucose was also elevated in the confirmed cases. By contrast, the liver transaminases ALT and AST did not differ significantly between the groups, despite earlier literature documenting hepatic involvement in COVID-19, with some studies reporting elevated transaminase activity in a substantial proportion of patients during the course of illness. The authors suggest that elevated LDH likely reflects tissue injury and systemic inflammation, while increased GGT points toward hepatobiliary involvement, though they acknowledge that previous findings on GGT in COVID-19 have been inconsistent, with some studies reporting no difference between confirmed and suspected cases.

To probe the relationships among these markers more deeply, the team performed Pearson correlation analysis within the RT-PCR-positive group. C-reactive protein correlated positively with AST, ALT, LDH, and GGT, and ferritin showed similar positive correlations with all four enzymes. The strongest associations were seen between the inflammatory markers and LDH and GGT, hinting at a coupling between systemic inflammation and the tissue or hepatobiliary injury these enzymes signal. This interlocking pattern of inflammation and organ-associated enzyme release reinforces the idea that the biochemical disturbances of COVID-19 are not isolated abnormalities but components of a coordinated pathological process.

The most consequential result emerged from the multivariable logistic regression analysis. When the significant biochemical variables were entered into a single model, only two markers remained independently associated with RT-PCR positivity: LDH, with an odds ratio of 1.008 per unit increase and a 95 percent confidence interval of 1.002 to 1.013 and a P value of 0.004, and GGT, with an odds ratio of 0.949, a 95 percent confidence interval of 0.903 to 0.997, and a P value of 0.039. CRP, despite its dramatic univariate elevation in confirmed cases, did not retain independent significance in the model. The direction of the GGT association, with higher values slightly reducing the odds of RT-PCR positivity, is counterintuitive and underscores the complexity of interpreting these markers in a multivariable framework.

The authors are careful to frame these findings appropriately. Because the study was retrospective and cross-sectional, the observed associations between LDH, GGT, and RT-PCR positivity cannot be interpreted as evidence of predictive or causal relationships. The regression model was built primarily from available laboratory parameters and did not account for all potential clinical confounders such as age, comorbidities, and disease severity, meaning residual confounding cannot be excluded. Moreover, the RT-PCR-negative group, though retested to reduce false negatives, was not systematically screened for alternative respiratory pathogens or other inflammatory conditions, so some of these patients may have had other infections or inflammatory diseases that influenced their laboratory profiles. The single-hospital design and modest sample size further limit generalizability, and clinical outcomes such as oxygen requirement, intensive care admission, and mortality were not available for all patients and could not be assessed.

Despite these caveats, the study offers a practical message for resource-constrained settings. The constellation of higher white cell and neutrophil counts, lower lymphocyte and eosinophil counts, and elevated LDH, GGT, CRP, and ferritin provides a recognizable laboratory fingerprint of confirmed COVID-19 that can be generated with standard hospital analyzers. In places where RT-PCR capacity is limited or turnaround times are long, such patterns may support clinical judgment while definitive testing is pending. The researchers call for prospective multicenter studies with larger cohorts, comprehensive clinical characterization, appropriate adjustment for confounding factors, and evaluation of patient outcomes to confirm these findings and determine whether LDH and GGT can ultimately earn a place alongside RT-PCR in the diagnostic toolkit for COVID-19 and beyond.

Subject of Research: Hematological and biochemical differences between RT-PCR-positive and RT-PCR-negative patients with suspected COVID-19 in Yemen

Article Title: Hematological and biochemical alterations in patients with suspected COVID-19 infection with negative and positive RT-PCR swabs

Article References: Bin Dahman, L. S., Bakarman, A. A., Al-Nakhbi, N. A., Al-Haddad, A. M., Bin-Talib, A. H., Al-Saadi, H. A., Bashatah, S. T., Al-Yazidi, N. S., Al-Houti, M. S., & Bin-Dheyab, M. O. (2026). Hematological and biochemical alterations in patients with suspected COVID-19 infection with negative and positive RT-PCR swabs. Acta Biochimica Polonica, 73, Article 16764. https://doi.org/10.3389/abp.2026.16764

Image Credits: AI Generated

DOI: 10.3389/abp.2026.16764

Keywords: COVID-19, SARS-CoV-2, RT-PCR, lactate dehydrogenase, gamma-glutamyl transferase, CRP, ferritin, lymphopenia, neutrophilia, Yemen, biomarkers, retrospective study

The starting point was NSC158011, a thioamide compound known chemically as N-1-naphthalenyl-2-(phenylthiol) ethane thioamide. Earlier work had identified this molecule as an inhibitor of Cryptosporidium lactate dehydrogenase, or LDH, the enzyme the parasite uses to regenerate the molecular currency NAD+ during its energy-generating fermentation of sugars. Because C. parvum lacks many of the metabolic pathways available to its host cells, it relies heavily on this fermentation route, making LDH an attractive drug target. Blocking the enzyme should, in principle, starve the parasite of usable energy while leaving host metabolism, which can draw on far more flexible pathways, comparatively unharmed. The challenge was that NSC158011 itself was only moderately potent, and like many first-generation enzyme inhibitors it carried liabilities that limited its usefulness as a drug candidate.

To improve on the parent compound, the researchers turned to systematic structural optimization. They constructed a virtual library of 1,440 derivatives of NSC158011, varying the chemical groups attached to the thioamide core in a deliberate, computationally guided fashion. Each virtual candidate was then assessed through molecular docking, a technique that predicts how well a small molecule fits into the three-dimensional structure of its protein target. Docking scores served as a filter: rather than synthesizing the entire library, the team selected 29 derivatives whose predicted binding to the LDH active site looked most promising. This triage strategy, common in modern medicinal chemistry, dramatically reduced the cost and time of the campaign by concentrating laboratory effort on the molecules most likely to succeed.

The synthesis and screening phase delivered a clear signal. Of the 29 derivatives made and tested, eight showed significant inhibitory effects on lactate dehydrogenase, outperforming the original NSC158011. That hit rate, nearly a third of the synthesized compounds, suggests that the docking-based selection was effective and that the thioamide scaffold tolerates substantial modification without losing its ability to engage the enzyme. For the authors, the eight active inhibitors confirmed the central hypothesis of the study: that the anti-parasitic activity of this chemical family flows from its interaction with LDH, and that potency can be improved by tuning the molecule’s fit within the enzyme’s binding pocket.

Enzyme inhibition is only the first hurdle, however. A drug candidate must also reach and act within infected cells without poisoning them. In laboratory tests using cells infected with C. parvum, two of the eight potent LDH inhibitors stood out. Both markedly reduced the number of parasites inside host cells, and both did so with reduced toxicity compared with the parent compound. That combination, stronger anti-parasitic effect alongside a better safety margin, is precisely what medicinal chemists hope to achieve through structure-based optimization, and it elevated the two derivatives to lead compound status in the study.

The next question was whether the compounds could work in living animals, where drug absorption, distribution, and the hostile environment of the gut all complicate the picture. The team used two complementary models. The first was the interferon-gamma knockout mouse, a standard experimental model of cryptosporidiosis in which the absence of this key immune signaling molecule leaves animals highly susceptible to persistent infection. The second was the calf, a natural host for C. parvum and the setting where the parasite inflicts its greatest economic damage in agriculture. In both systems, the derivatives showed potent anti-parasitic effects, reducing the parasite burden established by infection.

Beyond simply lowering parasite counts, the treatment appeared to protect the architecture of the infected intestine. Cryptosporidium infection classically causes atrophy of the intestinal villi, the finger-like projections that absorb nutrients, and this tissue damage contributes substantially to the malnutrition and wasting seen in severe disease. In the treated animals, the researchers observed that the derivatives alleviated this villus atrophy, suggesting that clearing the parasite allows the gut lining to begin recovering. For calves in particular, where cryptosporidiosis can stunt growth and spread rapidly through herds, a therapy that both kills the parasite and limits tissue injury would carry real practical value.

To understand how the compounds produced these broader benefits, the researchers examined molecular markers of gut integrity and inflammation. Treatment was associated with increased expression of three tight junction proteins, ZO-1, Occludin, and Claudin-1, which form the seals between adjacent intestinal cells and are essential for maintaining the barrier that keeps gut contents out of the bloodstream. At the same time, the compounds lowered expression of Caspase-1, an inflammatory protein involved in driving damaging inflammatory responses. Together these changes paint a picture of a gut barrier being restored and inflammation being dialed back as the parasite burden falls, consistent with the observed healing of the villi.

The team also looked one level deeper, at the ecosystem of microbes and metabolites in the gut. Analysis of the gut microbiota in treated calves showed that the derivatives significantly restored the abundance of beneficial flora, the microbial populations associated with healthy digestion and resistance to pathogens. Complementary metabolomic profiling revealed that treatment regulated key metabolites, including isocitric acid, an intermediate of cellular energy metabolism, and ornithine, an amino acid central to the urea cycle and to intestinal tissue repair. These findings suggest that effective anti-parasitic therapy does not operate in isolation: by removing the parasite, the drugs appear to allow the entire gut ecosystem, from microbes to metabolic chemistry, to rebalance itself toward health.

The study’s authors position the two derivatives as promising lead compounds for further development as anti-cryptosporidiosis agents, with relevance both to livestock production and to public health. The path from lead compound to approved drug remains long, requiring optimization of pharmacokinetics, formal safety testing, and clinical or field trials, and the current study does not resolve those questions. But the work demonstrates a complete early-stage pipeline: a validated metabolic target, a computationally guided chemical library, confirmed enzyme inhibition, cellular efficacy with reduced toxicity, and efficacy in both a susceptible mouse model and a natural animal host, with mechanistic evidence of tissue and microbiome recovery. For a disease with few treatment options, particularly nitazoxanide, which performs inconsistently in the malnourished and immunocompromised patients who need it most, any new chemical starting point is significant. If the two derivatives survive the rigors of preclinical and clinical development, they could eventually offer a much-needed option against a parasite that sickens children and calves across the globe.

Subject of Research: Development of lactate dehydrogenase inhibitors as drug candidates against Cryptosporidium parvum

Article Title: Novel inhibitors against Cryptosporidium parvum through blocking its energy metabolism

Article References: Xu, C., Ji, Y., Sha, Q., & Li, K. (2026). Novel inhibitors against Cryptosporidium parvum through blocking its energy metabolism. PLOS Neglected Tropical Diseases, 20(10), e0014742. https://doi.org/10.1371/journal.pntd.0014742

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014742

Keywords: Cryptosporidium parvum, lactate dehydrogenase, drug discovery, molecular docking, cryptosporidiosis, intestinal parasite, gut microbiota, metabolomics, tight junction proteins, livestock health, neglected tropical diseases, lead compounds

The research team, led by Florian Scheichel of University Hospital St. Pölten with colleagues from the Medical University of Innsbruck and Kepler University Hospital in Linz, confronted a methodological puzzle that has plagued the field for decades. Almost all existing data on steroid response in primary CNS lymphoma come from retrospective series with wildly inconsistent information about steroid dose, duration, and timing. In those studies, patients received steroids before their diagnostic imaging for variable reasons, and the intervals between scans and drug administration were uncontrolled. Some patients may have already regressed before their first scan; others may have progressed after an initial regression that nobody captured. The result was a literature in which reported response rates ranged from nearly ninety percent of tumors showing no change to nearly sixty percent showing progression, numbers so divergent that no reliable picture of steroid sensitivity could be drawn. The Austrian group designed their study to break this cycle by exploiting a window that every patient passes through but that had never been systematically imaged: the days immediately after biopsy, when the diagnosis is already secured and steroids are given routinely for symptom relief.

The prospective design was elegant in its simplicity. Patients with suspected primary large B-cell lymphoma of the central nervous system, who were scheduled for stereotactic or endoscopic biopsy at three Austrian neurosurgical centers, were enrolled after informed consent. Patients with systemic lymphoma, immunocompromise, or Epstein-Barr virus positivity were excluded, and the final diagnosis had to be confirmed as primary large B-cell CNS lymphoma. After surgery, all centers administered a comparable steroid protocol: an initial bolus of 40 milligrams of dexamethasone, followed by 16 milligrams daily, with the dose halved every three days. Critically, the team planned an additional thin-slice MRI five to ten days after surgery, timed to compare directly with the preoperative navigational MRI used to plan the biopsy. Patients were excluded if that second scan would have delayed definitive cancer treatment, a safeguard that cost the study thirteen of its forty screened candidates but protected the integrity of the remaining data. Eighteen patients formed the prospective volumetric cohort, ten women and eight men, none of whom suffered surgical complications that would have confounded the volume measurements.

The volumetric analysis was performed with 3D Slicer, an open-source platform for medical image computing, by segmenting the contrast-enhancing lesion on both the preoperative and post-steroid scans and calculating relative volume change. The results revealed a spectrum of behavior far wider than the word regression suggests. In 83.3 percent of cases the tumor shrank after steroids, with a median volume reduction of 40 percent, but the individual responses ranged from a barely perceptible one percent shrinkage to a dramatic 77 percent collapse. Meanwhile, in 16.7 percent of patients, the tumor did something counterintuitive: it grew despite the steroid therapy, with a median progression of 46 percent and one case expanding by 94 percent. Mean tumor volume fell from 16.1 cubic centimeters before surgery to 11.9 cubic centimeters after steroids across the cohort. The median interval between scans was seven days, and the median cumulative postoperative dexamethasone dose was 112 milligrams, with nearly all patients receiving between 104 and 140 milligrams.

Perhaps the most clinically consequential negative finding was what did not explain this heterogeneity. The researchers tested whether the degree of tumor volume change correlated with the cumulative steroid dose, the dose normalized to body surface area, or the duration of therapy, and found no evidence for any of these relationships. The Kendall-tau correlation between volume change and cumulative dose was a negligible 0.072 with a p-value of 0.694, and duration fared no better. In other words, a tumor that melted away under a standard steroid taper was not simply receiving more drug than one that expanded; the difference appears to reside in the biology of the malignant clone itself. There was, however, a suggestive signal involving lactate dehydrogenase, or LDH, the serum enzyme long known to be an adverse prognostic marker in both systemic lymphomas and primary CNS lymphoma. In the prospective cohort, higher preoperative LDH levels showed a trend toward correlation with worse radiological response, and when the analysis was expanded to a combined cohort of 31 patients, that correlation became statistically significant, with higher LDH predicting less tumor shrinkage on two-dimensional measurement.

That combined cohort was the study’s second analytical layer. Because eighteen patients were too few for meaningful survival statistics, the team merged their prospective data with a carefully filtered retrospective cohort of thirteen patients from their own earlier 2021 multicenter study. The inclusion criteria were strict: retrospective patients needed at least two preoperative MRI scans with steroid therapy initiated no more than two days before the first scan and continuing or uninterrupted between scans, ensuring that any observed change genuinely reflected the drug’s effect rather than uncontrolled timing. For this combined group, response was quantified as the change in the largest cross-sectional tumor area on an axial MRI slice, a two-dimensional measure that was validated against the volumetric results in the prospective patients with an intraclass correlation coefficient of 0.87, indicating excellent agreement between the two methods. In the combined cohort, 74.2 percent of tumors regressed and 25.8 percent progressed, and the two groups proved comparable in age, tumor size, Karnofsky performance status, involvement of deep brain structures, and treatment type, meaning the response pattern was not simply a proxy for having a bigger or more advanced tumor.

The survival analysis delivered the study’s headline result. Patients whose tumors regressed after steroids had a median overall survival of 31.4 months, while those whose tumors progressed despite steroids survived a median of just 3.9 months, a difference that reached statistical significance in Kaplan-Meier analysis with a p-value of 0.015. A sensitivity analysis excluding the three patients who had received steroids before biopsy preserved the finding, and a stratification using RECIST-style thresholds, at least 30 percent regression, stable disease, or at least 20 percent progression, showed a consistent trend, with median survival not reached in the regression group, 11.1 months for stable disease, and 3.9 months for progression. The authors then turned to Firth-corrected Cox regression, a statistical method designed for small samples with few events, and built a multivariable model including radiological response, age, Karnofsky performance status, and whether induction therapy contained high-dose methotrexate. In that model, tumor progression despite steroids carried a hazard ratio of 3.37 for death, with a p-value of 0.02 and a 95 percent confidence interval of 1.21 to 9.35, suggesting that radiological response is an independent prognostic factor rather than a mere echo of known predictors.

The biological interpretation is where the finding becomes genuinely provocative. Corticosteroids kill lymphoid cells through glucocorticoid receptor-mediated apoptotic pathways, and the sensitivity of a given lymphoma to this mechanism may reflect broader properties of drug responsiveness in the malignant clone. If a tumor cannot be pushed into apoptosis by a potent glucocorticoid, the reasoning goes, it may also respond poorly to methotrexate and the other cytotoxic agents that form the backbone of CNS lymphoma therapy. Progression despite steroids would then be a visible, early, and essentially free signal of multidrug resistance, available from scans that are already part of routine care. This would align with the rare but well-documented historic cases in which steroids alone produced prolonged, occasionally years-long remissions, presumably in patients with extreme intrinsic sensitivity. The authors are careful to frame their conclusions as exploratory: the sample was small, the survival analysis necessarily incorporated retrospective data, and confounders such as salvage therapies and treatment heterogeneity could not be fully controlled. Overall survival was chosen over progression-free survival precisely because follow-up strategies across centers were inconsistent.

The study also carries a practical warning that neurosurgeons and emergency physicians ignore at their patients’ peril. Preoperative steroids can render biopsies inconclusive, with histological disappearance of malignant B-cells reported in up to 52 percent of pretreated cases and threefold increases in non-diagnostic biopsies described in prior work. Guidelines therefore recommend avoiding steroids before tissue acquisition whenever clinically feasible, yet patients frequently arrive at specialized centers already steroid-treated because of neurological deterioration earlier in their pathway. The new data add a dimension to this dilemma: the same steroid exposure that risks obscuring the diagnosis may also, if properly documented with serial imaging, yield prognostic information that could eventually help stratify patients into risk-adapted treatment protocols. The Austrian team emphasizes that larger prospective multicenter studies are needed to validate the survival finding and to unravel the molecular mechanisms that determine why one patient’s lymphoma dissolves under dexamethasone while another’s grows through it. If those mechanisms can be identified, the humble steroid challenge, long viewed as a diagnostic nuisance, could be reframed as one of the cheapest prognostic tests in neuro-oncology.

Subject of Research: Radiological response of primary central nervous system lymphoma to corticosteroid therapy and its prognostic value for overall survival

Article Title: Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study

Article References: Scheichel, F., Pinggera, D., Rossmann, T., Popadic, B., Aspalter, S., Schön, V., Woehrer, A., Dorostkar, M. M., Dorfer, C., Freyschlag, C. F., & Marhold, F. (2026). Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study. Journal of Neuro-Oncology, 179(2), Article 63. https://doi.org/10.1007/s11060-026-05773-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05773-3

Keywords: primary CNS lymphoma, corticosteroid therapy, MRI, overall survival, dexamethasone, lactate dehydrogenase, prognostic factors, volumetric analysis, methotrexate, neuro-oncology, Kaplan-Meier analysis, drug sensitivity

Extensive-stage small cell lung cancer accounts for the majority of small cell lung cancer diagnoses at presentation, meaning the disease has already spread beyond the chest. The modern treatment paradigm pairs platinum-based chemotherapy with immune checkpoint inhibitors, and in selected patients who respond well, sequential thoracic radiotherapy is added to consolidate control of disease in the chest. Yet even after this intensive sequence, outcomes vary enormously between individuals, and clinicians have historically lacked validated markers to re-evaluate prognosis once radiotherapy is complete. The new research addresses precisely this gap, asking whether blood-based signals measured at the post-radiotherapy checkpoint carry meaningful information about subsequent survival.

The prognostic nutritional index, or PNI, is a composite measure calculated from serum albumin concentration and peripheral lymphocyte count. It captures two biologically important dimensions: nutritional status and cellular immune competence. Low albumin reflects catabolic stress and poor nutritional reserve, while lymphopenia signals depleted adaptive immunity, a particular concern in patients receiving immunotherapy whose antitumor activity depends on functional T cells. Lactate dehydrogenase, by contrast, is an enzyme released when cells are damaged or turning over rapidly, and elevated serum levels have long been associated with high tumor burden and aggressive disease biology in small cell lung cancer.

The study retrospectively analyzed 203 patients with extensive-stage small cell lung cancer who had completed first-line chemoimmunotherapy followed by sequential thoracic radiotherapy and who reached the post-radiotherapy assessment point without death or disease progression. Blood samples were collected at two timepoints: before the start of systemic therapy and four to six weeks after completion of thoracic radiotherapy. The researchers dichotomized PNI at a cutoff of 56.7, determined through their analysis, and classified lactate dehydrogenase against the institutional upper limit of normal of 245 units per liter. Overall survival and progression-free survival were both calculated from the date of the post-radiotherapy assessment, ensuring that the prognostic signals reflected the post-treatment state rather than pretreatment characteristics.

The results were unambiguous. During follow-up, 147 deaths and 179 progression events occurred. Higher post-radiotherapy PNI was independently associated with better overall survival and progression-free survival, while elevated post-radiotherapy lactate dehydrogenase was associated with poorer outcomes on both endpoints. In multivariable models adjusting for other clinical factors, both markers retained their significance, suggesting that they capture prognostic information beyond what standard clinical variables provide. The findings align with a growing body of evidence that host factors, nutrition and immune status, modulate outcomes in the immunotherapy era, not merely tumor burden alone.

Perhaps the most intriguing result came from tracking how PNI changed over the course of treatment. The researchers grouped patients according to their transition from baseline to post-radiotherapy PNI categories and found that these trajectories provided additional prognostic information beyond the post-radiotherapy value alone, with statistical significance for both overall survival and progression-free survival. In practical terms, a patient whose nutritional-immune index held steady or improved through chemoimmunotherapy and radiotherapy fared differently from one whose index declined to the same final value, hinting that the direction of change carries its own biological message about treatment tolerance and reserve capacity.

By combining the two markers, the team constructed an exploratory post-radiotherapy risk stratification with three tiers. The separation was stepwise and clinically substantial: median overall survival was 27 months in the low-risk group, 14 months in the intermediate-risk group, and just 9 months in the high-risk group. Compared with the low-risk group, the high-risk group had markedly poorer overall survival, with a hazard ratio of 5.122 and a 95 percent confidence interval of 3.103 to 8.454, and poorer progression-free survival, with a hazard ratio of 2.918 and a 95 percent confidence interval of 1.835 to 4.642, both statistically significant. A more than threefold difference in median survival between the extremes, derived from two inexpensive blood tests, illustrates how much prognostic granularity routine laboratory data can provide when deployed at the right moment in the treatment course.

The authors subjected their main multivariable model to bootstrap internal validation, a statistical resampling technique that estimates how much a model’s apparent accuracy is inflated by overfitting to the development dataset. The optimism-corrected concordance indices were 0.685 for overall survival and 0.641 for progression-free survival, values that indicate moderate discriminative ability, respectable for a model built on routinely collected clinical variables but short of the performance needed for definitive clinical decision-making. The team was careful to frame the stratification as exploratory, emphasizing that prospective external validation in independent cohorts is required before the approach can be applied in clinical practice.

The implications, if validated, could be significant for how follow-up care is tailored after aggressive multimodality therapy. Patients identified as high risk at the post-radiotherapy checkpoint might be candidates for intensified surveillance imaging, earlier enrollment in clinical trials of escalation strategies, or closer attention to nutritional and supportive care, while low-risk patients might safely avoid unnecessary interventions. Because both markers are already measured in standard clinical practice, implementing such a stratification would require no new assays, no additional cost, and no change to treatment workflows, only a shift in when clinicians look at the numbers and what they infer from them.

The study also carries caveats inherent to its design. As a retrospective analysis from a single institution, it cannot exclude selection biases in which patients received sequential thoracic radiotherapy or reached the post-radiotherapy assessment, and the cutoff values for PNI and lactate dehydrogenase were derived from the same cohort in which they were tested, raising the familiar risk of optimistic thresholds. Still, the work adds to a compelling narrative in modern oncology: that the body’s own nutritional and inflammatory state, read through simple blood counts and chemistry panels, can be as informative as expensive molecular profiling. For a disease as relentless as extensive-stage small cell lung cancer, any tool that helps clinicians and patients see the road ahead more clearly is welcome news, and this study offers a promising, if still provisional, addition to the prognostic toolkit.

Subject of Research: Prognostic value of post-radiotherapy nutritional and metabolic blood markers in extensive-stage small cell lung cancer

Article Title: Post-radiotherapy prognostic nutritional index and lactate dehydrogenase for risk stratification in extensive-stage small cell lung cancer after completion of chemoimmunotherapy and sequential thoracic radiotherapy

Article References: Cui, W., Jiang, M., Wang, M., Liu, J., & Chen, D. (2026). Post-radiotherapy prognostic nutritional index and lactate dehydrogenase for risk stratification in extensive-stage small cell lung cancer after completion of chemoimmunotherapy and sequential thoracic radiotherapy. BMC Cancer. https://doi.org/10.1186/s12885-026-17062-3

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17062-3

Keywords: extensive-stage small cell lung cancer, thoracic radiotherapy, chemoimmunotherapy, prognostic nutritional index, lactate dehydrogenase, risk stratification, overall survival, progression-free survival, prognostic markers, radiation oncology, biomarkers, oncology

EMT is a fundamental developmental program that is hijacked in cancer. During EMT, cells lose the apical-basal polarity and cell-cell adhesion molecules, such as E-cadherin, that hold epithelial sheets together, and they instead express mesenchymal markers including N-cadherin, vimentin, and transcriptional repressors of the Snail, Slug, Twist, and Zeb families. In lung biology, this program is deeply implicated in both pathological fibrosis and carcinoma progression, since the same signaling cascades that mobilize epithelial plasticity during wound repair can be co-opted by tumor cells to detach, migrate, invade surrounding tissue, and ultimately seed metastases. Transforming growth factor beta, or TGF-β, is the most potent and widely studied inducer of EMT, activating downstream SMAD-dependent transcription as well as non-canonical pathways involving MAPK, PI3K-AKT, and Rho GTPases.

What has become increasingly clear over the past decade is that EMT is not merely a change in gene expression; it is a wholesale reorganization of cellular metabolism. Epithelial cells, which rely heavily on mitochondrial oxidative phosphorylation to generate ATP, must rewire their energetic machinery to support the demanding biosynthetic needs of a migrating, proliferating cell. Aerobic glycolysis provides rapid ATP and, critically, diverts glycolytic intermediates into branching anabolic pathways, including the pentose phosphate pathway for nucleotide synthesis and serine biosynthesis routes for lipid and amino acid generation. This metabolic flexibility is thought to be a prerequisite for successful EMT rather than simply a byproduct of it, and teasing apart cause from consequence is precisely the challenge that the new work addresses.

The research team focused on lung epithelial cells because the lung represents a clinical arena in which EMT-linked processes carry enormous weight. Idiopathic pulmonary fibrosis involves fibroblast activation and epithelial cell state transitions driven in part by TGF-β, while lung cancers, including non-small cell lung carcinoma, frequently display hybrid epithelial-mesenchymal phenotypes associated with drug resistance and metastatic spread. Understanding whether glycolytic reprogramming is a driver or a passenger in the TGF-β-induced transition of lung epithelial cells therefore has implications that extend from basic cell biology to therapeutic strategy, because metabolic enzymes are, in principle, druggable targets in a way that master transcription factors often are not.

Technically, the investigation combined TGF-β stimulation of lung epithelial cell models with measurements of glycolytic flux, lactate production, and the expression of key glycolytic enzymes such as hexokinase 2, phosphofructokinase, and lactate dehydrogenase A. These functional readouts were integrated with assessments of EMT marker expression, including the loss of E-cadherin and the gain of vimentin and N-cadherin, to establish a temporal and causal relationship between metabolic shift and phenotypic conversion. Such paired metabolic and molecular phenotyping is essential because TGF-β is known to alter numerous cellular processes simultaneously, and only carefully timed interventions can reveal which changes are required for EMT to proceed and which are secondary consequences of it.

The broader literature supports the plausibility of a causal link. Hypoxia-inducible factor 1 alpha, a master regulator of glycolytic gene expression, is stabilized not only by low oxygen but also by TGF-β signaling through mechanisms involving reactive oxygen species and mTOR pathway activation. At the same time, TGF-β suppresses the expression of PPAR gamma coactivator 1 alpha, a key driver of mitochondrial biogenesis, thereby tilting the balance away from oxidative metabolism. Glycolytic enzymes themselves have been reported to moonlight as transcriptional co-regulators; for example, certain glycolysis-associated factors can influence the activity of EMT transcription factors, creating feedback loops in which metabolism and gene expression reinforce one another. If such loops operate in lung epithelial cells, blocking glycolysis could potentially arrest or reverse the EMT program rather than merely slowing cellular energy production.

Therapeutically, the implications are considerable. Drugs that target glycolysis, ranging from hexokinase inhibitors to lactate dehydrogenase inhibitors, have been explored in preclinical cancer models for years, although clinical translation has been complicated by the dependence of normal tissues, including the brain and red blood cells, on glucose metabolism. The value of the new work lies in narrowing the therapeutic window: if glycolytic dependency is specifically induced during the EMT transition in lung epithelial cells, then transient metabolic intervention could be timed to coincide with windows of tumor plasticity, such as during the emergence of resistance to targeted therapies or immune checkpoint inhibitors, when EMT-associated states are thought to be most prominent.

The study also speaks to a conceptual shift in how the field understands cell state transitions. EMT is now recognized not as a binary switch but as a spectrum of hybrid states, with cells occupying partial epithelial-mesenchymal phenotypes that may be particularly aggressive and drug tolerant. Metabolic profiling adds an additional axis to this landscape: hybrid cells may display intermediate glycolytic dependency, fully mesenchymal cells may be the most glycolytic, and reversibility of the process may depend on whether the metabolic reprogramming has been consolidated through epigenetic modification. Stable chromatin changes at EMT gene loci could lock in a mesenchymal state even after the original TGF-β signal dissipates, suggesting that metabolic interventions would need to occur early in the transition to be effective.

For patients with lung disease, the distance between mechanistic cell biology and clinical benefit remains substantial, and the authors’ findings should be understood as foundational rather than immediately actionable. Nevertheless, the convergence of TGF-β biology, metabolic reprogramming, and epithelial plasticity in lung cells offers a coherent framework for developing biomarkers that identify patients whose tumors or fibrotic lesions are undergoing active EMT, and for designing combination regimens in which metabolic inhibitors sensitize cells to existing TGF-β pathway antagonists, kinase inhibitors, or antifibrotic agents. As the field continues to map the metabolic architecture of cell state transitions, studies like this one bring the goal of intervening in cancer progression and fibrosis at the level of cellular identity, rather than merely cellular proliferation, steadily closer to realization.

Subject of Research: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article Title: The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells

Article References: Huang, S.-W., Chen, H.-C., Peng, S.-Y., Chuang, C.-H., Chen, B.-C., Cheng, W.-H., Cools, J. M. T., Neoh, M.-M., Hsiao, S.-H., & Hsu, M.-J. (2026). The role of aerobic glycolysis in TGF-β-induced epithelial-to-mesenchymal transition in lung epithelial cells. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03322-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03322-5

Keywords: aerobic glycolysis, Warburg effect, TGF-beta, epithelial-to-mesenchymal transition, lung epithelial cells, EMT, cancer metastasis, metabolic reprogramming, lactate dehydrogenase, pulmonary fibrosis, cell death discovery, glycolytic flux